Business Analysis for Harris and Harris Group

1351 Words3 Pages

Harris & Harris Group

Since 1983, Harris & Harris Group has a strong reputation for investing in companies with proprietary technology. Their main focus is on interdisciplinary life science companies, where innovative biology intersects with innovation in areas such as electronics, chemistry, physics, materials, information, technology, engineering and mathematics. Harris & Harris Group differs from competitors because their investments are not divided into specific funds. Currently, they invest in 25 small portfolio companies with total investments equaling $172 million.

Distinctive Approach in Biotechnology

We see lucrative potential in Harris & Harris Group because of their unique focus on founding, incubating and building transformative companies from disruptive science. Their focus on biology, which has become their approach to building high value life companies, distinguishes them from competitors. They believe in interdisciplinary innovation that will solve current and future life challenges. Tulane Endowment is interested in investing in innovations that will radically change the future and improve the lives of individuals. We are further interested in Harris & Harris Group and the biotechnology industry for its youthfulness and fast growth. With an expected growth over next 10 years at 10.8 percent, we believe demand will increase. Tulane Endowment seeks investments in industry segments with a rapid rate of technological change such as that of Harris & Harris. We have seen over the past several years the demand for therapeutic products and genetically modified crops increase, and therefore we believe this industry will remain in the growth stage of its economic life cycle throughout the length of our investment and ...

... middle of paper ...

...ed to other brands. Tulane Endowment sees Repairogen as a great opportunity for investment and seeks to support such start-ups, as there is much room for development and many opportunities both domestically and internationally to grow.

Valuation
Harris & Harris Group valuated Repairogen at $1,368,055 by using comparables. This is a high valuation for a company that is in the R&D stage. However, this company offers a very unique product with draw for customers in both the health and cosmetic industries. Repairogen’s exit strategy is a merger or acquisition, which is a typical exit strategy for the cosmetics industry and a safer exit strategy than an IPO. Tulane Endowment is very excited to provide funding to this company, because we believe that Repairogen has many opportunities to expand globally and gain a competitive advantage once it hits the cosmetics market.

More about Business Analysis for Harris and Harris Group

Open Document